Women's health venture funding has undergone a structural shift. Silicon Valley Bank's 2025 women's health report documented $2.6 billion in venture capital investment in 2024, up sharply year on year. McKinsey's 2024 analysis valued the broader women's health market opportunity at $1.7 trillion globally. Melinda French Gates and Wellcome Leap announced a major new initiative in late 2025 specifically targeting the gap between pharmaceutical R&D spending and women's health outcomes outside oncology.
But the capital is not distributed evenly. The vast majority of venture investment lands in the United States, where the translation infrastructure — regulatory consultants, specialist investors, reimbursement advisors, clinical trial management organisations with women's health expertise — is already in place. Europe is building, led by the UK's Wellcome Trust investments and the Nordic femtech ecosystem. Australia, despite world-class research inputs, captures a negligible share of global women's health venture capital.
The gap is not about scientific quality. It is about translation readiness. Australian researchers produce globally competitive work in endometriosis, fertility, and maternal health, but the pathway from a published finding to an investable venture with de-risked regulatory, clinical, and commercial milestones remains ad hoc. Without a dedicated translation layer, the value of that research is captured overseas — by US or European companies that license Australian IP, run their trials elsewhere, and bring products back to market at full freight.
This is the structural case for an Australian women's health translation platform: not to replicate what exists in Boston or London, but to build the missing infrastructure that allows Australian science to become Australian companies — generating jobs, trial capability, and exportable expertise that compounds over decades.
This essay is published while the proposed platform is in development; it may be revised as settings and partnerships are finalised. It does not constitute medical, legal, or investment advice.
Related insights
Australia
Australia's women's health research landscape: assets, gaps, and translation potential
Australia has world-class research programs in reproductive biology, maternal health, and hormonal medicine. The challenge is converting that science into ventures that reach patients — and the infrastructure gap that sits between discovery and adoption.
Economics
The workforce and economic case for women's health investment
Women's health is not a social good separate from economic policy. When chronic conditions go unaddressed, the costs show up in workforce participation, productivity, and downstream healthcare spend.
Ideas
Women's health is Australia's biggest underpriced asset
For all our talk of productivity and sovereign capability, we are overlooking one of the smartest investments we can make. Anthony Liveris argues that treating women's health as core economic policy could unlock national capability.